WOONSOCKET, R.I., Nov. 6, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced Prem Shah will be Group President, and will continue to report to David Joyner, President and Chief Executive Officer. In addition, the company announced the appointment of Steve Nelson as President, Aetna, and he will also report to Joyner. Both appointments are effective today.
As Group President, Shah will be responsible for the operational performance and integrated value creation across CVS Caremark, CVS Pharmacy, and the company's Health Care Delivery businesses.
Shah joined CVS Health in 2013 and has held leadership positions in the pharmacy benefit management, specialty pharmacy, and pharmacy businesses. He was most recently Executive Vice President and Chief Pharmacy Officer, CVS Health and President, Pharmacy and Consumer Wellness, with oversight and responsibility for the company's omnichannel pharmacy strategy. Prior to his most recent role, Shah held several senior leadership positions at CVS Health where he provided strategic oversight of pharmacy functions.
"Prem is a strong operator and innovator with deep experience across our businesses, and in his role, he will help me and the rest of our leadership team drive improvements in our financial and operational performance across our company," said Joyner. "I am confident in the future of our integrated model, and that Prem and Steve's leadership will help further position us to deliver greater value from our integrated business model."
Nelson has deep experience leading several managed care and health care delivery companies, and most recently served as Chief Executive Officer of ChenMed, a leading value-based primary care company. He is also a former Chief Executive Officer of UnitedHealthcare, a $200 billion division of UnitedHealth Group. During his tenure at UnitedHealth Group, Nelson held several leadership roles leading UnitedHealthcare's Commercial and Government businesses to significant improvements in growth, profitability, employee engagement and culture, and customer satisfaction.
"Steve is an industry veteran who has successfully led multiple segments of a diverse managed care company and driven innovation and growth throughout his career," said Joyner. "I will work closely with him and the team, building upon and accelerating the plan to advance Aetna forward."
About CVS Health
CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues — including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health — whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system — and their personal health care — by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.
Media contact
Ethan Slavin
860-273-6095
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor contact
Larry McGrath
800-201-0938
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$61.61 |
Daily Change: | 6.27 11.33 |
Daily Volume: | 26,184,508 |
Market Cap: | US$77.630B |
November 06, 2024 October 16, 2024 September 12, 2024 August 27, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB